Asahi Kasei Pharma begins phase III study of promising CIPN prevention therapy, Recomodulin to enhance treatment options worldwide: Chelmsford, Massachusetts Thursday, July 3, 202 ...

CHELMSFORD, Mass. & NOVI, Mich. & DÜSSELDORF, Germany & TOKYO, July 02, 2025--Asahi Kasei Pharma has started trial drug administration in a Phase III study of ART-123 in Japan for CIPN.